NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
Toronto – October 1, 2019 (CNW) – Canada House Wellness Group (CSE:CHV) (“Canada House” or the “Company”), announced today that its wholly owned subsidiary, Abba Medix Corp. (“Abba”), commenced sale of its Abba branded cannabis flower.
“Selling our own branded cannabis is a huge milestone for us. The Abba team has worked hard over the last few months to get our facility running and fully licensed,” said Michael Orrbrooke, Chief Revenue Office, Canada House Wellness and President, Abba Medix. “Our Abba branded Purple Bud is available for sale to registered Abba patients as of today.”
Abba produces handcrafted, premium quality, medical grade cannabis for patients seeking safe solutions for their complex to common health and wellness needs. Currently, Abba has one strain, an Indica dominant Purple Bud, ready for sale. Purple Bud comes from a cross between Jamaican Sativa and Afghani Indica. The flower is named for its purple and lavender hues which offer a piney, sweet aroma of sandalwood.
Abba’s 22,000 sq. ft. indoor production facility in Pickering, Ontario, has dried flower packaged and ready for sale. Abba continues to ramp up production towards its goal of between 2,000 and 3,000 kg of dried flower on an annualized basis at its Pickering, Ontario facility. It is now in full perpetual grow with regular harvests every three weeks.
“This is a strong step forward for Canada House as we continue on our Path to Profitability,” said Chris Churchill-Smith, CEO, Canada House. “Selling our own cannabis to Canadian patients is significant as we continue to drive the business forward. We are looking forward to finalizing our extraction strategy and having derivative products ready for Cannabis 2.0 and look forward to additional positive news in the weeks and months ahead.”
About Canada House Wellness Group Inc.
Canada House Wellness Group Inc. is the parent company of Abba Medix Corp., a Licensed Producer in Pickering, Ontario that produces high quality medical grade cannabis; Canada House Clinics Inc., with clinics across the country that work directly with primary care teams to provide specialized cannabinoid therapy services to patients suffering from complex medical conditions; and Knalysis Technologies, a provider of fully customizable, cloud-based software that links physician, provider, and patient to data that supports treatment with medical cannabis.
Canada House Wellness Group’s goal is to become the leading cultivator of premium craft cannabis and provider of cannabinoid therapy, targeting the medical cannabis markets globally. Please visit www.canadahouse.ca.
For further information, please contact:
Liana Del Medico, Director of Communications & Investor Relations
Canada House Wellness Group Inc. 416-553-3820
Cautionary Statement Regarding Forward-Looking Information. This press release contains forward-looking statements, including statements that relate to, among other things, the Company’s clinic, production and technology businesses, its future plans, the Company’s markets, objectives, goals, strategies, intentions, beliefs, expectations and estimates, and can generally be identified by the use of words such as “may”, “will”, “could”, “should”, “would”, “likely”, “possible”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective” and “continue” (or the negative thereof) and words and expressions of similar import. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Material assumptions used to develop forward-looking information in this news release include, among other things, the regulations related to cannabis use under the Access to Cannabis for Medical Purposes Regulations and the act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts, passed by the Canadian Federal government, making cannabis legal for recreational use by October 17, 2018; Company liquidity and capital resources, including the availability of additional capital resources to fund its activities; level of competition; the ability to adapt products and services to the changing market; the ability to attract and retain key executives; and the ability to execute strategic plans. Additional information about material factors that could cause actual results to differ materially from expectations and about material factors or assumptions applied in making forward-looking statements may be found in the Company’s most recent annual and interim Management’s Discussion and Analysis under “Risk and Uncertainties” as well as in other public disclosure documents filed with Canadian securities regulatory authorities. The Company does not undertake any obligation to update publicly or to revise any of the forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, except as required by law.
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.